Memantine for lewy body disorders: Systematic review and meta-analysis

Shinji Matsunaga, Taro Kishi, Nakao Iwata

研究成果: Article査読

17 被引用数 (Scopus)

抄録

Objective To clarify whether memantine is more efficacious in several outcomes and safer than placebo in patients with Lewy body disorders, we performed a meta-analysis of memantine in patients with Lewy body disorders. Methods The meta-analysis included randomized controlled trials of memantine for Lewy body disorders in all patients with Lewy body disorders. Motor function, activities of daily living, Neuropsychiatric Inventory, Mini-Mental State Exam, discontinuation rate, and individual side effects were evaluated. Results No significant effects of memantine on motor function scores, Mini-Mental State Exam scores, Neuropsychiatric Inventory scores, and activity of daily living scores were found. However, memantine was superior to placebo in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change scores (standardized mean difference: -0.26; 95% confidence interval: -0.51 to -0.02; z = 2.08; p = 0.04; two studies; N = 258). Dropout due to all causes, inefficacy, or adverse events were similar in both groups. Moreover, no significant differences in serious adverse events, somnolence/tiredness, stroke, dizziness/vertigo, and confusion were found between the groups. Conclusion Our results suggest that memantine did not have a benefit for the treatment of Lewy body disorders in cognition and motor function. However, memantine may be superior to placebo for the overall impression of the disorders. Further, memantine is well tolerated.

本文言語English
ページ(範囲)373-383
ページ数11
ジャーナルAmerican Journal of Geriatric Psychiatry
23
4
DOI
出版ステータスPublished - 01-04-2015

All Science Journal Classification (ASJC) codes

  • 老年医学
  • 精神医学および精神衛生

フィンガープリント

「Memantine for lewy body disorders: Systematic review and meta-analysis」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル